Innate immune activation by cGMP-AMP nanoparticles leads to potent and long-acting antiretroviral response against HIV-1

Chukwuemika Aroh, Zhaohui Wang, Nicole Dobbs, Min Luo, Zhijian Chen, Jinming Gao, Nan Yan

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

HIV-1 evades immune detection by the cGAS-STING cytosolic DNA-sensing pathway during acute infection. STING is a critical mediator of type I IFN production, and STING agonists such as cGMP-AMP (cGAMP) and other cyclic dinucleotides elicit potent immune and antitumor response. In this article, we show that administration of cGAMP, delivered by an ultra–pH-sensitive nanoparticle (NP; PC7A), in human PBMCs induces potent and long-acting antiretroviral response against several laboratory-adapted and clinical HIV-1 isolates. cGAMP-PC7A NP requires endocytosis for intracellular delivery and immune signaling activation. cGAMP-PC7A NP-induced protection is mediated through type I IFN signaling and requires monocytes in PBMCs. cGAMP-PC7A NPs also inhibit HIV-1 replication in HIV+ patient PBMCs after ex vivo reactivation. Because pattern recognition receptor agonists continue to show more clinical benefits than the traditional IFN therapy, our data present important evidence for potentially developing cGAMP or other STING agonists as a new class of immune-stimulating long-acting antiretroviral agents.

Original languageEnglish (US)
Pages (from-to)3840-3848
Number of pages9
JournalJournal of Immunology
Volume199
Issue number11
DOIs
StatePublished - Dec 1 2017

Fingerprint

Adenosine Monophosphate
Nanoparticles
HIV-1
Anti-Retroviral Agents
Pattern Recognition Receptors
Endocytosis
Cyclic AMP
Monocytes
HIV
DNA
Infection

ASJC Scopus subject areas

  • Immunology

Cite this

Innate immune activation by cGMP-AMP nanoparticles leads to potent and long-acting antiretroviral response against HIV-1. / Aroh, Chukwuemika; Wang, Zhaohui; Dobbs, Nicole; Luo, Min; Chen, Zhijian; Gao, Jinming; Yan, Nan.

In: Journal of Immunology, Vol. 199, No. 11, 01.12.2017, p. 3840-3848.

Research output: Contribution to journalArticle

@article{54287bfcd894400c8c7cfc368a278b87,
title = "Innate immune activation by cGMP-AMP nanoparticles leads to potent and long-acting antiretroviral response against HIV-1",
abstract = "HIV-1 evades immune detection by the cGAS-STING cytosolic DNA-sensing pathway during acute infection. STING is a critical mediator of type I IFN production, and STING agonists such as cGMP-AMP (cGAMP) and other cyclic dinucleotides elicit potent immune and antitumor response. In this article, we show that administration of cGAMP, delivered by an ultra–pH-sensitive nanoparticle (NP; PC7A), in human PBMCs induces potent and long-acting antiretroviral response against several laboratory-adapted and clinical HIV-1 isolates. cGAMP-PC7A NP requires endocytosis for intracellular delivery and immune signaling activation. cGAMP-PC7A NP-induced protection is mediated through type I IFN signaling and requires monocytes in PBMCs. cGAMP-PC7A NPs also inhibit HIV-1 replication in HIV+ patient PBMCs after ex vivo reactivation. Because pattern recognition receptor agonists continue to show more clinical benefits than the traditional IFN therapy, our data present important evidence for potentially developing cGAMP or other STING agonists as a new class of immune-stimulating long-acting antiretroviral agents.",
author = "Chukwuemika Aroh and Zhaohui Wang and Nicole Dobbs and Min Luo and Zhijian Chen and Jinming Gao and Nan Yan",
year = "2017",
month = "12",
day = "1",
doi = "10.4049/jimmunol.1700972",
language = "English (US)",
volume = "199",
pages = "3840--3848",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "11",

}

TY - JOUR

T1 - Innate immune activation by cGMP-AMP nanoparticles leads to potent and long-acting antiretroviral response against HIV-1

AU - Aroh, Chukwuemika

AU - Wang, Zhaohui

AU - Dobbs, Nicole

AU - Luo, Min

AU - Chen, Zhijian

AU - Gao, Jinming

AU - Yan, Nan

PY - 2017/12/1

Y1 - 2017/12/1

N2 - HIV-1 evades immune detection by the cGAS-STING cytosolic DNA-sensing pathway during acute infection. STING is a critical mediator of type I IFN production, and STING agonists such as cGMP-AMP (cGAMP) and other cyclic dinucleotides elicit potent immune and antitumor response. In this article, we show that administration of cGAMP, delivered by an ultra–pH-sensitive nanoparticle (NP; PC7A), in human PBMCs induces potent and long-acting antiretroviral response against several laboratory-adapted and clinical HIV-1 isolates. cGAMP-PC7A NP requires endocytosis for intracellular delivery and immune signaling activation. cGAMP-PC7A NP-induced protection is mediated through type I IFN signaling and requires monocytes in PBMCs. cGAMP-PC7A NPs also inhibit HIV-1 replication in HIV+ patient PBMCs after ex vivo reactivation. Because pattern recognition receptor agonists continue to show more clinical benefits than the traditional IFN therapy, our data present important evidence for potentially developing cGAMP or other STING agonists as a new class of immune-stimulating long-acting antiretroviral agents.

AB - HIV-1 evades immune detection by the cGAS-STING cytosolic DNA-sensing pathway during acute infection. STING is a critical mediator of type I IFN production, and STING agonists such as cGMP-AMP (cGAMP) and other cyclic dinucleotides elicit potent immune and antitumor response. In this article, we show that administration of cGAMP, delivered by an ultra–pH-sensitive nanoparticle (NP; PC7A), in human PBMCs induces potent and long-acting antiretroviral response against several laboratory-adapted and clinical HIV-1 isolates. cGAMP-PC7A NP requires endocytosis for intracellular delivery and immune signaling activation. cGAMP-PC7A NP-induced protection is mediated through type I IFN signaling and requires monocytes in PBMCs. cGAMP-PC7A NPs also inhibit HIV-1 replication in HIV+ patient PBMCs after ex vivo reactivation. Because pattern recognition receptor agonists continue to show more clinical benefits than the traditional IFN therapy, our data present important evidence for potentially developing cGAMP or other STING agonists as a new class of immune-stimulating long-acting antiretroviral agents.

UR - http://www.scopus.com/inward/record.url?scp=85034752751&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034752751&partnerID=8YFLogxK

U2 - 10.4049/jimmunol.1700972

DO - 10.4049/jimmunol.1700972

M3 - Article

VL - 199

SP - 3840

EP - 3848

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 11

ER -